InvestorsHub Logo
Followers 188
Posts 15268
Boards Moderated 1
Alias Born 06/15/2003

Re: None

Wednesday, 03/20/2019 10:54:51 AM

Wednesday, March 20, 2019 10:54:51 AM

Post# of 1174
Long ELLXF article. Interesting excerpt.

https://thegreenfund.com/elixinol-global-seeing-high-profits-from-diverse-investment

The Burning Issue of ODC Approval

Elixinol Global’s pharmaceutical grade medicinal cannabis company—formerly known as Elixinol Pty Ltd—is the NSW-based Nunyara Pharma.

Nunyara is currently developing a state-of-the-art growing facility in Northern NSW and has been left waiting for cannabis license approvals from the Office of Drug Control (ODC) for more than a year.

Once the licenses have been granted the company will begin using its high-tech greenhouses to produce the raw materials needed to manufacture its pre-existing CBD formulations. This will make Nunyara one of the few Australian companies that is capable of cultivating, manufacturing and distributing high-quality cannabis products to the Australian market.


“We’ve had plans for some time now to create a cultivation and manufacturing facility for high-grade medical cannabis in Australia”

– Paul Benhaim, Elixinol CEO


“Now, high-grade medical cannabis in Australia includes CBD and THC, because the government doesn’t differentiate them yet. I think they might wake up to the reality one day, but for the time being, we’re incorporating both of those under the Nunyara name.”

“We have applied for our licenses with the Office of Drug Control, more than one year ago, when the Office stated that they would give us our licenses within twenty days. But we are very hopeful that our licenses will be granted in the not-too-distant future, and have shown this by buying land that is perfectly suited to the medical cannabis division, and the needs of the Australia market.”


Like Hemp Foods Australia, Nunyara’s commercial focus will also be settled squarely on Australia for the time being.

While Nunyara is not opposed to the future exportation of its’ product line, Benhaim confirmed that its’ current focus is on fine-tuning the ideal method to bring the company’s cannabis products to market, as delays from the ODC are preventing it from commencing cultivation activities.